AusBiotech Ltd. CEO Hands Over Leadership After Stellar Contribution
AusBiotech Chairman, Julie Phillips has today announced that long-time CEO of the Australian
industry organisation, Dr Anna Lavelle, will hand over the leadership after more than 11 years of
service to the Australian biotechnology industry - to be succeeded by AusBiotech’s current Chief
Operating Officer, Mr Glenn Cross.
The changes will take effect from 1 September 2016 and see Dr Lavelle’s tenure at AusBiotech continue in the role of Principle Advisor to the Board.
Dr Anna Lavelle was recently named among the 100 most influential people in global life sciences, as determined through nominations and selections from an international panel of experts and peers and reported in Scientific American Worldview: A Global Biotechnology Perspective (2015).
Ms Phillips, said: “Anna is respected, visionary and eminent, as well as talented, tenacious and a dedicated advocate for our industry and we have been very fortunate to have her expertise. AusBiotech has gone from strength-to-strength under Anna’s leadership. Of the many achievements we saw during her time as CEO the delivery to the industry of the landmark reform, the Research and Development (R&D) Tax Incentive, is a highlight. Anna is quite rightly proud of her part in delivering this initiative which delivered hundreds of millions of dollars to the sector in cash as tax refunds – this among other many things, we each have to thank her for.”
Ms Phillips also announced that AusBiotech COO, Mr Glenn Cross, would step into the role of CEO on 1 September, after a decade of service. At the same time Lorraine Chiroiu will assume the role of Deputy CEO after almost eight years as national Communications Manager and more recently as Chief Industry Affairs Officer.
Ms Phillips said: “We are fortunate to have such a depth of talent and experience in our organisation, and the Board is delighted to welcome Glenn and Lorraine to their new roles. “The Board is confident that the new arrangement will provide a smooth transition and continued strong leadership team for AusBiotech as it works to progress the growth of the Australian life sciences industry.”
Glenn has spent most of his working life in life sciences having been a founder of DePuy Australia (now a J&J company), the first employee of Becton Dickinson Australia, CEO of Vision Systems Instrumentation and other senior executive roles in the industry.
Glenn is well known to members and has achieved a great deal, such as encouraging investor interest in Australian technology and being pivotal in increasing focus in Australian medical technologies.
The changes will take effect from 1 September 2016 and see Dr Lavelle’s tenure at AusBiotech continue in the role of Principle Advisor to the Board.
Dr Anna Lavelle was recently named among the 100 most influential people in global life sciences, as determined through nominations and selections from an international panel of experts and peers and reported in Scientific American Worldview: A Global Biotechnology Perspective (2015).
Ms Phillips, said: “Anna is respected, visionary and eminent, as well as talented, tenacious and a dedicated advocate for our industry and we have been very fortunate to have her expertise. AusBiotech has gone from strength-to-strength under Anna’s leadership. Of the many achievements we saw during her time as CEO the delivery to the industry of the landmark reform, the Research and Development (R&D) Tax Incentive, is a highlight. Anna is quite rightly proud of her part in delivering this initiative which delivered hundreds of millions of dollars to the sector in cash as tax refunds – this among other many things, we each have to thank her for.”
Ms Phillips also announced that AusBiotech COO, Mr Glenn Cross, would step into the role of CEO on 1 September, after a decade of service. At the same time Lorraine Chiroiu will assume the role of Deputy CEO after almost eight years as national Communications Manager and more recently as Chief Industry Affairs Officer.
Ms Phillips said: “We are fortunate to have such a depth of talent and experience in our organisation, and the Board is delighted to welcome Glenn and Lorraine to their new roles. “The Board is confident that the new arrangement will provide a smooth transition and continued strong leadership team for AusBiotech as it works to progress the growth of the Australian life sciences industry.”
Glenn has spent most of his working life in life sciences having been a founder of DePuy Australia (now a J&J company), the first employee of Becton Dickinson Australia, CEO of Vision Systems Instrumentation and other senior executive roles in the industry.
Glenn is well known to members and has achieved a great deal, such as encouraging investor interest in Australian technology and being pivotal in increasing focus in Australian medical technologies.